Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis

Area of Science:

• Dermatology and Immunology
• Cardiology and Metabolic Diseases

Background:

• Psoriasis is linked to cardiometabolic and cardiovascular diseases.
• Biologic therapies targeting TNF-α, IL-23, and IL-17 may offer benefits beyond skin improvement, potentially impacting cardiometabolic health.

Purpose of the Study:

• To retrospectively evaluate the impact of biologic therapies on cardiometabolic disease indicators in patients with psoriasis.
• To assess changes in body mass index, metabolic markers, and blood pressure following treatment with biologics.

Main Methods:

• Retrospective analysis of 165 psoriasis patients treated with TNF-α, IL-17, or IL-23 biologics from January 2010 to September 2022.
• Collected data on body mass index, HbA1c, lipid profiles (total cholesterol, HDL-C, LDL-C, TG), uric acid (UA), and blood pressure at baseline, week 12, and week 52.
• Correlated baseline Psoriasis Area and Severity Index (PASI) with cardiometabolic parameters.

Main Results:

• Baseline PASI positively correlated with TG and UA, and negatively with HDL-C.
• Infliximab (IFX) treatment showed increased HDL-C at week 12.
• Adalimumab (ADA) treatment resulted in decreased UA levels at week 12.
• Secukinumab (IXE) treatment led to decreased HDL-C at week 52.
• TNF-α inhibitors demonstrated increased HDL-C at week 12 and decreased UA at week 52, though results varied between time points.

Conclusions:

• Biologic therapy, particularly TNF-α inhibitors, may offer benefits for hyperuricemia and dyslipidemia in psoriasis patients.
• While specific outcomes varied by drug and time point, the study suggests a potential positive influence on cardiometabolic health.
• Further research is warranted to elucidate the precise mechanisms and long-term effects of these biologics on cardiometabolic disease indicators.